Hagen Brett R, Chief Accounting Officer of Kalaris Therapeutics Inc ($KLRS), made one open market sale of common shares in the last year, totaling $8,135. His most recent sale occurred on March 26, 2025. Among 11,678 insiders with sales, his activity ranks 11,314th by value, well below the average of $8.6 million across about 6 transactions each. He reported no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 20, 2026 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 1915 | $6.72 | 0.0000 | 18,702,418 | 100.00% | 0.01% |
| March 19, 2026 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | A | Stock Option (Right to Buy) | 60800 | $0.00 | 60,800.0000 | 18,702,418 | 9999.99% | 0.33% |
| April 10, 2025 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | A | Stock Option (Right to Buy) | 50262 | $0.00 | 50,262.0000 | 5,043,357 | 9999.99% | 1.00% |
| March 26, 2025 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 907 | $8.97 | 1,925.0000 | 5,043,357 | 32.03% | 0.02% |
| Feb. 21, 2025 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 96 | $10.08 | 2,832.0000 | 0 | 3.28% | 0.00% |
| Jan. 23, 2025 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 32 | $9.45 | 2,932.0000 | 0 | 1.08% | 0.00% |
| Jan. 23, 2025 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 4 | $9.94 | 2,928.0000 | 0 | 0.14% | 0.00% |
| Jan. 10, 2025 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 332 | $0.44 | 68,174.0000 | 0 | 0.48% | 0.00% |
| Nov. 19, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 554 | $0.55 | 68,506.0000 | 0 | 0.80% | 0.00% |
| Nov. 5, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 1655 | $0.86 | 69,060.0000 | 0 | 2.34% | 0.00% |
| Oct. 22, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 486 | $0.77 | 70,715.0000 | 0 | 0.68% | 0.00% |
| Oct. 21, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 479 | $0.78 | 71,201.0000 | 0 | 0.67% | 0.00% |
| Oct. 3, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 301 | $0.81 | 71,680.0000 | 0 | 0.42% | 0.00% |
| Aug. 19, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 544 | $0.76 | 71,981.0000 | 0 | 0.75% | 0.00% |
| Aug. 5, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 1692 | $0.73 | 72,525.0000 | 0 | 2.28% | 0.00% |
| July 19, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 479 | $0.75 | 74,698.0000 | 0 | 0.64% | 0.00% |
| July 22, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 481 | $0.74 | 74,217.0000 | 0 | 0.64% | 0.00% |
| July 2, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 304 | $0.72 | 75,177.0000 | 0 | 0.40% | 0.00% |
| May 17, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 541 | $0.75 | 75,481.0000 | 0 | 0.71% | 0.00% |
| May 3, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 1597 | $0.80 | 76,022.0000 | 0 | 2.06% | 0.00% |
| April 22, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 480 | $0.75 | 77,619.0000 | 0 | 0.61% | 0.00% |
| April 19, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 473 | $0.75 | 78,099.0000 | 0 | 0.60% | 0.00% |
| April 2, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 281 | $0.77 | 78,572.0000 | 0 | 0.36% | 0.00% |
| Feb. 20, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 494 | $0.70 | 78,853.0000 | 0 | 0.62% | 0.00% |
| Feb. 8, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 11150 | $0.67 | 79,347.0000 | 0 | 12.32% | 0.00% |
| Feb. 5, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 5792 | $0.67 | 90,497.0000 | 0 | 6.02% | 0.00% |
| Jan. 23, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 901 | $0.67 | 96,289.0000 | 0 | 0.93% | 0.00% |
| Jan. 4, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 310 | $0.64 | 97,190.0000 | 0 | 0.32% | 0.00% |
| Dec. 27, 2023 | Kalaris Therapeutics, Inc. | $KLRS | Hagen Brett R | Chief Accounting Officer | S | Common Stock | 28335 | $0.74 | 97,500.0000 | 0 | 22.52% | 0.00% |